SKI V

• Description :

  SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) . SKI V induces apoptosis and has antitumor activity[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Apoptosis; PI3K; SphK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ski-v.html

• Purity :

  98.95

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C1/C(OC2=CC=CC=C12)=C/C3=CC=C(O)C(O)=C3

• Molecular Formula :

  C15H10O4

• Molecular Weight :

  254.24

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]French KJ, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63 (18) :5962-9.|[2]French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318 (2) :596-603.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [24418-86-8]